Merck CEO Says Drugmaker Is ‘Restrained’ on Price Increases
- Frazier says he’s optimistic about tax reform under Trump
- CEO isn’t interested in big mergers, seeks value in the labs
Kenneth Frazier, chief executive officer of Merck & Co.
Photographer: Chris Goodney/BloombergThis article is for subscribers only.
Merck & Co. keeps a disciplined approach to drug pricing and is “restrained” when it comes to price hikes, Chief Executive Officer Ken Frazier said Thursday in an interview.
“I’m not saying we’re perfect,” he said Thursday after speaking on a panel at the Forbes Healthcare Summit in New York. “There will always be an individual drug in an individual year that you can point to and say, ‘That looks large in relation to others.’ But if you look at the whole portfolio, you will see that Merck has tended to be rather restrained when it comes to drug prices.”